Business context and reporting period
Issuer identification: The supplied filing is Tivic Health Systems, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2023; it does not identify Valion Bio, Inc. as the registrant. Tivic develops bioelectronic medicine products and sells its FDA-approved ClearUP sinus device through online and reseller channels.
Key financial metrics
Amounts below are in millions of dollars unless noted; the comparative period is the three months ended March 31, 2022.
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Revenue | $0.376 | $0.428; down 12% |
| Gross profit and margin | $0.113; 30.1% | $0.070; 16.4% |
| Operating expenses | $2.229 | $2.311 |
| Operating loss | $2.116 | $2.241 |
| Net loss | $2.116 | $2.240 |
| Operating cash flow | $(2.426) | $(2.168) |
| Investing cash flow | $(0.094) | $(0.006) |
| Financing cash flow | $4.170 | $0 |
At March 31, cash and cash equivalents were $5.167 million, working capital approximately $4.9 million, total assets $7.101 million, and total liabilities $1.896 million. Liabilities included $0.505 million in operating lease liabilities; the filing reports no borrowings. Cash increased from $3.517 million at year-end 2022. Cash burn from operations rose year over year.
Material changes versus prior period
- Revenue fell by $52,000, primarily as unit sales declined 27%; higher average selling prices partly offset the volume decline. Direct-to-consumer unit sales fell 34%, and retail unit sales fell 9%.
- Cost of sales decreased 27% to $263,000, and gross margin increased to 30.1% from 16.4%. Management attributed lower variable costs to manufacturing and fulfillment savings; lower sales volume raised fixed cost per unit.
- Research and development expense rose $89,000 to $490,000, while sales and marketing expense declined $226,000 to $458,000. General and administrative expense increased $55,000 to $1.281 million.
- On February 13, Tivic sold 20 million shares at $0.25 per share, raising $5.0 million gross and approximately $3.6 million net. Shares outstanding rose from 9.68 million at December 31, 2022 to 29.68 million at March 31, 2023. The offering also included 1 million underwriter warrants at a $0.3125 exercise price.
Outlook, risks and unusual items
- Going concern and financing: Management said cash and financial resources may be insufficient for anticipated needs during the 12 months following issuance of the statements. The filing states that substantial doubt exists about the company’s ability to continue as a going concern. Management expects additional losses and says further capital will be needed; the availability and terms of financing are uncertain.
- Operating plans: Management is targeting higher-value customer segments, price increases, more selective marketing, broader wholesale distribution, product improvements, and continued research and development. It expects lower product costs from new manufacturing and fulfillment arrangements, but provides no quantified revenue, earnings, or cash-flow guidance.
- Listing risk: Nasdaq notified Tivic that its share price had been below the $1 minimum bid for 30 consecutive business days. The initial compliance deadline was July 25, 2023; management said it expected to implement a reverse split. Delisting could constrain access to capital.
- Potential dilution: A $100 million shelf registration statement became effective in February 2023; the company reported no proceeds raised under it as of the filing. The February offering and warrants increased the potential share count. The underwriter’s option to buy 3 million additional offering shares expired unexercised.
- Other risks and commitments: The company cited supply-chain costs and availability, inflation, macroeconomic and banking-market uncertainty, and dependence on third-party manufacturers. A fulfillment agreement imposed a $25,000 minimum monthly purchase beginning April 1, 2023. The company reported no material litigation or off-balance-sheet arrangements.
- Subsequent management change: CFO Veronica Cai resigned effective April 28, 2023, and Kimberly Bambach was appointed interim CFO. The filing describes a $125,000 separation payment, subject to execution and non-revocation of a release.
Important facts for investors to verify
- Confirm the intended issuer: the filing supplied is for Tivic Health Systems, Inc., not Valion Bio, Inc.
- Track cash burn, financing availability, and any updates to the going-concern assessment or cash runway.
- Verify whether price increases, channel expansion, and lower manufacturing costs improve unit sales and gross margin in subsequent quarters.
- Check Nasdaq bid-price compliance, any reverse split, and the effect of further equity issuance or warrant exercise on dilution.
- Assess progress and costs for clinical studies, product development, and the company’s ability to turn ClearUP sales into sustainable cash generation.